Preview

Rational Pharmacotherapy in Cardiology

Advanced search

AMLODIPINE IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE: FOCUS ON ANTIATHEROSCLEROTIC PROPERTIES

https://doi.org/10.20996/1819-6446-2010-6-1-77-83

Full Text:

Abstract

Author discusses antiatherosclerotic effects of dihydropyridine calcium channel blocker, amlodipine, in patients with coronary artery disease. Results of randomized clinical trials PREVENT (2000), CAPARES (2000), CAMELOT (2004) and ENCORE II (2009) are analyzed.

About the Author

Yu. M. Lopatin
Volgograd State Medical University, Volgograd Regional Cardiology Center
Russian Federation

pl. Pavshih Bortsov 1, 400131 Volgograd

Gornaya Polyana, Volgograd 400008


References

1. Toyo-Oka T.; Nayler W.G. Third generation calcium entry blockers. Blood Press. 1996;5(4):206-8.

2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.

3. Julius S.; Kjeldsen S.E.; Weber M. et al for the VALUE trial group. Outcomes in hypertensive patients at high risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363(9426):2022-31.

4. Dahlöf B.; Sever P.S.; Poulter N.R. et al for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendr of lumetiazide as required; in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multi centre randomized controlled trial. Lancet 2005;366(9489):895-906.

5. Jamerson K.; Weber M.A.; Bakris G.L. et al. for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Eng lJ Med 2008;359(23):2417- 28.

6. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Car￾diology (ESC). J Hypertens 2007;25:1105-87.

7. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваскулярная терапия и профилактика 2008; 7(6 Приложение 2):1-32.

8. Deanfield J.; Detry J.; Sellier P. et al. Medical treatment of myocardial ischemia in coronary heart disease: Effect of drug regimen and irregular dosing in CAPE II trial. J Am Coll Cardiol 2002;40(5):917-25.

9. Henry P.D. Atherosclerosis; calcium; and calcium antagonists. Circulation 1985;72(3):456-9.

10. Henry P.D. Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharma￾col 1991;18 Suppl 1:S6–S10.

11. Fleckenstein A.; Frey M.; Zorn J.; Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends Pharmacol Sci 1987;8(12):496-501.

12. Waters D.; Lesperance J.; Francetich M. et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82(6):1940–53.

13. Lichtlen P.R.; Hugenholtz P.G.; Rafflenbeul W. et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335(8698): 1109–13.

14. Borhani N.O.; Mercuri M.; Borhani PA. et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996;276(10):785-91.

15. Mason R.P. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker am￾lodipine: review of the evidence. Atherosclerosis 2002;165(2):191-9.

16. Mason P.R.; Moring J.; Herbette L.G. An examination of the chemical and physical interactions of lipid soluble drugs with membranes in the heart and brain. In: Makriyannis A.; Castagnoli N.; editors. New Methods in Drug Research. Barcelona; Spain: J.R. Prous International Publishers; 1992

17. Zhang X.; Hintze T.H. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998;97(6):576-80.

18. Chen L.; Haught W.H.; Yang B. et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanism of antiatherosclerotic effects of vitamin E; lovastatin and amlodopine. J Am Coll Cardiol 1997;30(2):569-75.

19. Jørgensen B.; Simonsen S.; Endresen K. et al. Restenosis and clinical outcomes in patients treated with amlodipine after angioplasty :results from the Coronary AngioPlasty Amlodopine REStenosis Study (CAPARES). J Am Coll Cardiol 2000;35(3):592-9.

20. Tulenko T.N.; Laury-Kleintop L.; Walter M.F.; Mason R.P. Cholesterol; calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 1997;62(Suppl 2):S55- S66.

21. McMurray H.F.; Chahwala S. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20 Suppl A:S54-S56.

22. Mason R.P. Cytoprotective properties of long-acting calcium channel blockers: new mechanism of action (abstract). Am J Hypertension 1998:11:245A.

23. Roth M.; Eickelberg O.; Kohler E. et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996;93(11):5478-82.

24. Ikeda U.; Hojo Y.; Ueno S. et al. Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J Cardiovasc Pharmacol 2000;35(6):887-90.

25. Pitt B.; Byington R.P.; Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(13):1503-10.

26. Mancini G.B.J.; Miller M.E.; Evans G.W. et al. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol 2002;89(12):1414-6.

27. Walter M.F.; Jacob R.F.; Jeffers B. et al. Serum Levels of Thiobarbituric Acid Reactive Substances Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. A Longitudinal Analysis of the PREVENT Study. J Am Coll Cardiol 2004;44(10):1996–2002.

28. Walter M.F.; Jacob R.F.; Bjork R.E. et al. on behalf of the PREVENT Investigators. Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. The PREVENT Study. J Am Coll Cardiol 2008;51(12):1196–1202.

29. Jorgensen B.; Simonsen S.; Endresen K. et al. Restenosis and Clinical Outcome in Patients Treated With AmlodipineAfterAngioplasty: Results From the Coronary Angio Plasty Amlodipine RES tenosis Study (CAPARES). J Am Coll Cardiol 2000;35(3):592-9.

30. Berry C.; L’Allier P.L.; Grégoire J. et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2007;115(14):1851-7.

31. Nissen S.E.; Tuzcu E.M.; Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292(18):2217-25.

32. Lüscher Th.F.; Pieper M.; Tendera M. et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009;30(13):1590–7.

33. Цинамдзгвришвили Б.; Трапаидзе Д.; Лоладзе Н.; Рехвиашвили А. Сравнительная оценка влияния различных генериков амлодипина (Адипин; Нормодипин) и Норваска на эффективность контроля артериального давления. Georgian Med News 2008;(154):14-7

34. Дзизинский А.А.;Протасов К.В.; Федоршина О.В.Динамика пульсового давления на фоне лечения амлодипином и карведилолом у больных артериальной гипертонией. Лечащий врач 2008;(6):108-10.

35. Кательницкая Л.И.; Хаишева Л.А. Гендерные особенности клинического течения и лечения больных артериальной гипертонией. Рациональная Фармакотерапия в Кардиологии 2008;(1):76- 80.

36. Невзорова В.А.; Захарчук Н.В.; Плотникова И.В.. Состояние мозгового кровотока при гипертонических кризах и возможности его коррекции. РМЖ 2007;15(24):1801-4

37. Давидович И.М.; Блощинская И.А.; Петричко Т.А.. Артериальная гипертония и беременность: механизмы формирования; эффективность амлодипина (Нормодипина). РМЖ 2003;11(4):197- 200

38. Исследование PrIndex (PRESCRIPTION INDEX - "Мониторинг назначений лекарственных препаратов врачами"; апрель 2009; http://www.comcon-2.ru/default.asp?trID=284).


For citation:


Lopatin Y.M. AMLODIPINE IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE: FOCUS ON ANTIATHEROSCLEROTIC PROPERTIES. Rational Pharmacotherapy in Cardiology. 2010;6(1):77-83. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-1-77-83

Views: 586


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)